COMP <GO>
HNGE vs NVDA // ALTMAN Z-SCORE & DEBT/EQUITY
Hinge Health Inc. (NYSE) VS. NVIDIA Corporation (NASDAQ) • 15-METRIC TALLY: HNGE 4
— NVDA 10
▲ ALTMAN Z-SCORE & DEBT/EQUITY LEADER: NVDA
LAST: $114.32 (-2.21%) • MKT CAP: $9.43B
balance-sheet
12.12
LAST: $204.64 (-4.22%) • MKT CAP: $4.93T
balance-sheet
19.52
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (HNGE VS. NVDA)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | HNGE | NVDA | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 79.60% | 74.67% | +4.93 | HNGE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | 65.06% | -100.06 | NVDA | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 23.2x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 1.81% | 2.58% | -0.77 | NVDA | /fcf-yield <GO> |
| Operating Margin | -60.00% | 65.21% | -125.21 | NVDA | /operating-margins <GO> |
| Net Profit Margin | -60.00% | 63.66% | -123.66 | NVDA | /net-margins <GO> |
| Revenue Growth (YoY) | 50.60% | 83.38% | -32.78 | NVDA | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.02% | -0.02 | NVDA | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | 12.12 | 19.52 | -7.40 | NVDA | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 4/9 | +3.00 | HNGE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.70% | 9.01% | -1.31 | HNGE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 67.5 | 35.1 | +32.44 | HNGE | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.24 | 2.04 | -0.80 | NVDA | /macro-sensitivity <GO> |
| Forward P/E Multiple | 29.0x | 17.0x | +11.98 | NVDA | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $9.43B | $4.93T | -$4.92T | NVDA | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | HNGE REV | NVDA REV | HNGE GROSS % | NVDA GROSS % | HNGE FCF | NVDA FCF |
|---|---|---|---|---|---|---|
| FY 2026 | — | $215.94B | — | 71.1% | — | $96.68B |
| FY 2025 | $587.9M | $130.50B | 79.6% | 75.0% | $170.7M | $60.85B |
| FY 2024 | $390.4M | $60.92B | 76.8% | 72.7% | $48.0M | $27.02B |
| FY 2023 | $292.7M | $26.97B | 44.0% | 56.9% | -$77.1M | $3.81B |
| FY 2022 | — | $26.91B | — | 64.9% | — | $8.13B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
HNGE // BETA 1.24
NVDA // BETA 2.04